STTR Phase I: New Paradigm for Combination Drug Optimization and Discovery — NSF Award to DUET BIOSYSTEMS, INC (TN, $284,736)
The broader impact of this Small Business Innovation Research (STTR) Phase I project is in addressing directly the challenge of optimizing the use and discovery of drug combinations. Effective combination drug therapies optimize the therapeutic effects of these drugs and minimize harmful and/or uncomfortable side effec
| Award title | STTR Phase I: New Paradigm for Combination Drug Optimization and Discovery |
|---|---|
| Award ID | 2432890 |
| Awardee | DUET BIOSYSTEMS, INC |
| City | NASHVILLE |
| State | TN |
| Amount obligated | $284,736 |
| Principal investigator | Gerard Ostheimer |
| Program | SBIR Outreach & Tech. Assist, STTR Phase I |
| Start date | 03/01/2025 |
| Abstract | The broader impact of this Small Business Innovation Research (STTR) Phase I project is in addressing directly the challenge of optimizing the use and discovery of drug combinations. Effective combination drug therapies optimize the therapeutic effects of these drugs and minimize harmful and/or uncomfortable side effects. Many diseases, including cancer, Alzheimer’s, heart disease, and life-threatening infections, are treated by drugs used in combination. Amazingly, the use of these drug combina |
| Source | NSF Awards |
$799/mo
Try NSFGrants →